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INSURANCE CLAIMS AS A DEVICE FOR 
MEASURING THE PHARMACISTS 
SUBSTITUTION RIGHT IN A FRENCH 
DEPARTMENT
Mègnigbêto A, Le Lay K, Launois R
 
Rees France, Paris, France
 
OBJECTIVE:
 
 The use of generic drugs has not been as
successful as hoped in France. In order to increase their
use, rights of replacement have been given to pharmacists
through 1999. The aim of this study is to determine the
factors influencing prescription of generics by doctors
and generic substitutions by pharmacists.
METHODS: We have analyzed reimbursement data
from a Department (CPAM93) that has drug-dispensing
data from 15 June 2000. The AFSSAPS and the Sempex
Data databases were used to evaluate reimbursement
data. Chi-square and logistic regression tests were used to
establish determining factors for prescribing and replac-
ing with generic drugs.
RESULTS: The file analyzed contained 25,422 reim-
bursement prescription lines involving 6578 patients.
Sixty percent of the patients were women, 1964 carried
exemption certificates (EXOTM) and 953 received CMU
(general state health coverage). The average age of the pa-
tients was 43.3 years. The drugs belonging to the AFSSAPS
repertoire consisted of 3902 prescription lines. There
were 1257 generic drugs that could either be prescribed
by the doctor or dispensed in replacement. Three hun-
dred seventy five prescription lines were replaced by
pharmacists, or 12.42% of those that could have been re-
placed. Four products represented more than half of the
replaced drugs. The patient characteristics considered by
the pharmacist when replacing the drug were lack of
EXOTM, age below 65 years old, and the presence of
CMU. Prescriptions for generic drugs by the doctor made
up 53.50% of the generic prescription lines dispensed, al-
though only 18.20% of the lines reimbursed were on the
AFSSAPS listing. CMU, lack of an exemption certificate
(EXOTM) and age under 65 years old were the factors
taken into account by the doctor when prescribing ge-
neric drugs.
CONCLUSION: The use of generic drugs in France
could be much more widespread.
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PILOT STUDY TO DETERMINE THE 
DEMOGRAPHICS, REASONS, AND TYPES OF 
MEDICATIONS PURCHASED IN MEXICO BY 
US RESIDENTS
 
Calvillo JP, Lal LS
Texas Southern University, College of Pharmacy, Houston, TX, 
USA
OBJECTIVE: The objective of this research survey is to de-
termine the types of medications, reasons, and demograph-
ics of Americans going to Mexico to purchase medications.
METHODS: This is a survey in which a voluntary, self-
administered questionnaire consisting of twenty-four ques-
tions divided into three sections regarding patient demo-
graphics, information pertaining to the purchase, and in-
formation relating to the reasons why Americans chose to
purchase medications in Mexico, is utilized. The popula-
tion for this study consists of one hundred US citizens or
immigrants purchasing medications in Progresso, Mexico.
RESULTS: Results indicate that 60% of the participants
had some form of private insurance, 18% had Medicare,
and only 19% had no insurance at all. The number one
reason for which participants traveled to Mexico to pur-
chase medications is the lower price (85%) followed by
lack of insurance (22%), and not wanting to pay for a
physician’s office visit (17%). The treatment of infection
is listed by 41% of the participants as the condition for
which the medication they purchased is used. Hyperten-
sion (16%), and gastrointestinal disorders (13%) are the
next most common medical conditions listed. Ampicillin
(25%) is the number one medication purchased. Eighty-
six percent of the people surveyed purchased one to three
different types of medications, and 46% of the people
spent between eleven and fifty dollars for their purchases.
CONCLUSION: This pilot study indicates that Ameri-
cans are traveling to Mexico to purchase medications for
many reasons and for many different medical conditions.
Based on this study, the major reason for going outside
the country to purchase medications is the lower cost,
even for people with private insurance. Further studies
are needed to determine the specific implications and
possible problems associated with taking such drastic
steps to acquire the necessary medications by US citizens.
 
PHP8
 
THE USE OF ECONOMIC INFORMATION IN 
HOSPITAL FORMULARY DEVELOPMENT IN A 
FRENCH REGION
 
Späth HM, Charavel M, Morelle M, Carrère MO
GRESAC - UMR 5823 du CNRS, Lyon, France
OBJECTIVE: Over the last 15 years pharmacoeconomics
research has grown rapidly, but little is known about the
actual use of economic information in health-care deci-
sion-making. We conducted semi-structured interviews
with hospital pharmacists in a French region to deter-
mine the role of economic information in drug selection
for hospital formularies.
METHODS: We developed an interview schedule based
on a literature review and three pilot interviews. We in-
terviewed pharmacists in short stay hospitals with more
than 100 beds. Thirteen public hospitals (PH) and six pri-
vate clinics (PC) in the Rhone-Alpes region, in France,
were randomly selected. Interviews were taped and the
transcripts were coded independently by two researchers.
We compared the six PC, financed on a fee-for-service
basis, with the 13 PH, financed on a global budget basis,
by multiple correspondence analysis.
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RESULTS:
 
 In all hospitals the drug’s price and the quan-
tity prescribed have an influence on formulary decision-
making, especially for drugs used in the same indication
with similar effectiveness and safety. The drug’s price and
the quantity prescribed seem to have more impact on PH
than on PC. Information about costs avoided by the in-
clusion of a drug in the formulary might have an influ-
ence on decision-making: (1) time spent by nurses (5 PC
and 9 PH); (2) medical devices (2 PC and 5 PH); (3)
shorter hospital stays (2 PC and 4 PH). This information
has little (6 PC and 10 PH) or very little (3 PH) impact
and seems to have even less impact on PH than on PC.
Moreover, published economic evaluations have very lit-
tle impact on decision-making in all hospitals.
CONCLUSION: In hospital formulary development, eco-
nomic information is mostly used for cost-containment
considerations, especially in PH financed on a global
budget basis. The current use of information related to
economic evaluations and to costs avoided by the inclu-
sion of a drug is limited, compared to its potential use.
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NATIONAL DRUG LIST ON AVERAGE NUMBER 
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The Israeli National Health Law was enacted in January
1995, making health insurance both compulsory and uni-
versal. The law determined a basic list of health services
to which all residents are entitled, and stated that the
government is responsible for funding those health ser-
vices. The National List of Health Services was defined as
the 1994 formulary of Clalit Health Services, Israel’s
largest Sick Fund (3.5 million clients). After the law was
enacted and until December 2000, 152 new drugs were
added to the national formulary and none were removed.
Our hypothesis is that adding new drugs to a formulary
increases the number of prescriptions that patients re-
ceive.
OBJECTIVE: To determine if there was a change in the
average number of prescriptions given to patients of Cla-
lit Health Services in different age groups, between the
years 1996 and 2000.
METHODS: Clalit Health Services’ database was ac-
cessed to determine the number of prescriptions given to
patients in different age groups, who received drug ther-
apy in the years 1996 and 2000.
RESULTS: Children aged 0–18 years received 4.49 annual
prescriptions in 1996 vs. 5.00 in 2000 (D  11%). Patients
between ages 19–45 received 5.93 prescriptions in 1996 vs.
6.34 in 2000 (D  7%). The age group of 46–65 received
14.88 prescriptions in 1996 vs. 16.41 in 2000 (D  10%),
and the elderly age group (66) received 21.63 annual pre-
scriptions in 1996 vs. 33.18 in 2000 (D  53%).
CONCLUSIONS: After adding 152 new drugs to the Na-
tional Drug List, the most significant change in the num-
ber of annual prescriptions was seen in the elderly age
group. These patients are now clearly using more medica-
tions than they used five years ago, although this monthly
average of 2.8 prescriptions per patient is slightly lower
than has been published in other epidemiological studies
from Switzerland and Italy (3.2 to 4.0 on average).
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THE ROAD TO JAPAN/KOREA 2002: PROSPECTS 
FOR JAPANESE PHARMACOECONOMICS
 
Pang F
 
Kyoto University, Kyoto, Japan
 
OBJECTIVES:
 
 The aim of this study is to conduct an en-
vironmental assessment of the Japanese health-care sys-
tem as it enters the year 2002 with a focus on the pros-
pects of the use and impact of pharmacoeconomics. The
drivers, resistors and changes in stakeholder influence on
the pricing and prescribing of pharmaceuticals are exam-
ined as well as Japanese economic evaluations to evaluate
their state of the art and to highlight methodological con-
siderations for future studies.
METHODS: A review of the published and internet liter-
ature in English and Japanese on the Japanese health-care
system was conducted, supplemented by interviews with
representatives from academia, hospitals, pharmacies, the
medical press, industry and government. A systematic review
of Japanese economic evaluations was also conducted us-
ing databases (MEDLINE, OHE-HEED, NHS-EED), and
each study was assessed using a modified 36-point BMJ
quality checklist.
RESULTS: Debate regarding pricing reform has been
taking place since 1997 and submission of economic data
to the MHLW has been optional since 1992 although the
influence of these studies on pricing and reimbursement
is uncertain. Main barriers to economic evaluation are
the lack of Japanese-specific clinical/cost data, low num-
bers of trained pharmacoeconomists, lack of decision-
making expertise/knowledge and organizational disincen-
tives. Thirty-four Japanese economic evaluations were
identified (32 CCA, 1 CEA, 1 CMA), predominantly ad-
dressing screening or diagnostic issues and cancer. 63%
of studies used observational data; 37% contained disag-
gregated presentations, 23% applied discounting, 29%
employed sensitivity analysis and 50% reported ICERs.
CONCLUSIONS: Although Japan is considered a late-
adopter of pharmacoeconomics, there are several encour-
aging signs, e.g., rising numbers of Japanese economic
evaluations and methodological research taking place in
Japan on the Japanese EuroQol, generalizability, impact
and willingness-to-pay. This study offers insights into the
current status of Japanese pharmacoeconomics, particu-
larly barriers that need to be overcome for cost-effective-
ness to be influential on health-care decision-making in
Japan.
